CHRS
Coherus BioSciences Inc
1.10$
-3.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -76.9% | -359.5% | -132.8% | -12,871.9% | -10,235.6% | 8.0% | 32.4% | -11.5% | -114.3% | -68.0% | -7.7% | -328.4% | |
| 2.2% | 6.2% | 1.6% | 218.4% | 207.9% | 0.9% | 0.6% | 1.1% | 1.8% | 1.5% | 2.0% | 9.3% | |
| 35.6% | 55.7% | 14.4% | 2,317.8% | 2,236.3% | 9.4% | 8.0% | 15.7% | 24.0% | 16.8% | 10.4% | 40.2% | |
| 97.2% | 74.3% | 15.8% | 2,459.3% | 2,276.9% | 9.6% | 8.0% | 76.5% | 39.3% | – | – | – | |
| 91.4% | 303.3% | -83.8% | -329.9% | 661.8% | -32.0% | -7.3% | 13.0% | -37.6% | -14.3% | 20.9% | -13.9% | |
| 9.2% | 20.5% | 3.4% | 293.9% | 50.7% | 3.6% | 1.5% | 0.4% | 1.0% | 0.1% | 0.0% | 0.0% | |
| -1.7% | -23.1% | -3.4% | -283.9% | -76.3% | -3.6% | -3.0% | -42.4% | -79.1% | 56.2% | 86.3% | 889.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 20.3% | 4.3% | 0.5% | 1.8% | – | – | – | |
| 0.0% | 38.0% | 1.4% | -35.0% | 236.1% | -0.2% | -0.2% | -0.5% | -1.8% | -1.4% | – | – | |
| 321.5% | 332.9% | 52.6% | 4,688.6% | 4,688.6% | 20.5% | 46.7% | -0.2% | 23.7% | 0.0% | -83.7% | -665.9% | |
| 437.1% | 408.4% | 119.0% | 13,289.7% | 6,775.1% | 25.1% | 47.1% | 15.9% | 25.7% | 27.1% | -70.0% | -649.0% | |
| 356.3% | 26.1% | -17.5% | 126.2% | -3,506.7% | 29.4% | 76.4% | -38.0% | -167.6% | 15.3% | 8.6% | -88.0% | |
| -86.1% | -380.0% | -136.3% | -13,165.7% | -10,286.3% | 4.3% | 30.9% | -11.9% | -115.2% | -68.1% | -7.7% | -328.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.